Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  BioPharma  /  GNBT - Generex Biotechnology - Deel 3

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 3

703 Posts
Pagina: 1 2 3 4 5 6 ... 36 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 oktober 2008 19:38
    De tweeduizend post zijn gepasseerd, wat inhoudt dat het tijd is voor een derde deel GNBT

    --- Vorige delen ---
    Deel 2: www.iex.nl/forum/topic.asp?forum=215&...
    Deel 1: www.iex.nl/forum/topic.asp?forum=215&...

    --- Koersen ---
    www.iex.nl/stocks/stocks_detail.asp?I...
    quotes.nasdaq.com/asp/summaryquote.as...

    --- Informatie toevoegen? ---
    Om deze startpost uitgebreider te maken kunnen jullie concrete info/links mailen naar forum@iex.nl. Wij zullen deze informatie, mits geschikt, toevoegen aan deze starpost
  2. [verwijderd] 27 oktober 2008 13:41
    Generex Biotechnology Awarded New Drug Delivery Patent

    Company Expands Australian Patent Portfolio
    October 27, 2008: 08:00 AM EST

    WORCESTER, Mass., Oct. 27, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has received a new patent in Australia.

    The Australian Patent Office has granted the Company a patent titled Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application. The patent contains formulation and method claims to a pharmaceutical formulation comprising a macromolecular pharmaceutical agent in mixed micellar form, and metered dose device containing said formulation, for buccal administration.

    "We are pleased to include this latest patent to our expanding portfolio," said Rose Perri, the Company's Chief Operating Officer. "While we continue to move forward with the regulatory process in major markets, we continue to work on patent submissions for other jurisdictions."

    Generex currently holds an aggregate of 128 patents worldwide (21 of which are United States Patents) and has an aggregate of 134 patent applications pending in various jurisdictions.

  3. [verwijderd] 27 oktober 2008 14:22
    quote:

    toorg schreef:

    Generex Biotechnology Awarded New Drug Delivery Patent

    Company Expands Australian Patent Portfolio
    October 27, 2008: 08:00 AM EST

    WORCESTER, Mass., Oct. 27, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has received a new patent in Australia.

    The Australian Patent Office has granted the Company a patent titled Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application. The patent contains formulation and method claims to a pharmaceutical formulation comprising a macromolecular pharmaceutical agent in mixed micellar form, and metered dose device containing said formulation, for buccal administration.

    "We are pleased to include this latest patent to our expanding portfolio," said Rose Perri, the Company's Chief Operating Officer. "While we continue to move forward with the regulatory process in major markets, we continue to work on patent submissions for other jurisdictions."

    Generex currently holds an aggregate of 128 patents worldwide (21 of which are United States Patents) and has an aggregate of 134 patent applications pending in various jurisdictions.

    En het zoveeelste mooie bericht...maar de koers is zakkende en zakkende..0,29 en voorbeurs nog niets weer.
  4. [verwijderd] 27 oktober 2008 14:37
    Gedetailleerde koers
    GNBT - GENEREX BIOTECHNOLOGY CORP (US, Nasdaq)
    US markten Euronext Brussel Euronext Parijs Euronext Amsterdam Frankfurt (Xetra) Milaan (Borsa Italiana) Londen (LSE) Zurich Virt-X Madrid Canada TSX & TSX Venture Helsinki Copenhagen Stockholm

    Laatste koers Verschil


    0.29 USD 0.00 (0 %)
    Bid Ask
    0.29 0.30
    Bid Quantity Ask Quantity
    1300 100
    Volume Tijdstip
    11839 2008-10-27 14:36:01
    Slotkoers Openingskoers
    0.29 0.30
    Laagste v/d dag Hoogste v/d dag
    0.28 0.30

    ______________________ gebeurt weer niks hoor.
  5. [verwijderd] 27 oktober 2008 15:39
    Durf,

    Welk doel heeft jou aanwezigheid hier. de draadjes waar jij komt geeft meestal onrust mbt actie en reactie.
    Is het teveel gevraagd om enkel interessante info te geven. Het koersverkloop kunnen de meesten die in dit soort aandelen zitten/handelen toch wel op een of andere manier volgen zonder jou commentaar.
    Alvast dank voor je medewerking.
  6. [verwijderd] 29 oktober 2008 16:08
    quote:

    Durvinvest" schreef:

    Gedetailleerde koers
    GNBT - GENEREX BIOTECHNOLOGY CORP (US, Nasdaq)
    US markten Euronext Brussel Euronext Parijs Euronext Amsterdam Frankfurt (Xetra) Milaan (Borsa Italiana) Londen (LSE) Zurich Virt-X Madrid Canada TSX & TSX Venture Helsinki Copenhagen Stockholm

    Laatste koers Verschil


    0.29 USD 0.00 (0 %)
    Bid Ask
    0.29 0.30
    Bid Quantity Ask Quantity
    1300 100
    Volume Tijdstip
    11839 2008-10-27 14:36:01
    Slotkoers Openingskoers
    0.29 0.30
    Laagste v/d dag Hoogste v/d dag
    0.28 0.30

    ______________________ gebeurt weer niks hoor.
    Laatste koers Verschil


    0.29 USD 0.00 (0 %)
    ____________________________ en na 2 dagen nog steeds niks..nog steeds 0,29??
  7. [verwijderd] 29 oktober 2008 18:24
    quote:

    Durvinvester schreef:

    [quote=Durvinvest"]
    Gedetailleerde koers
    GNBT - GENEREX BIOTECHNOLOGY CORP (US, Nasdaq)
    US markten Euronext Brussel Euronext Parijs Euronext Amsterdam Frankfurt (Xetra) Milaan (Borsa Italiana) Londen (LSE) Zurich Virt-X Madrid Canada TSX & TSX Venture Helsinki Copenhagen Stockholm

    Laatste koers Verschil
    0.29 USD 0.00 (0 %)
    ______________________ gebeurt weer niks hoor.
    [/quote] Laatste koers Verschil

    0.29 USD 0.00 (0 %)
    ____________________________ en na 2 dagen nog steeds niks..nog steeds 0,29??
    Hoezo niks,
    0.3059 Up 0.0159 (5.48%)
    Day's Range: 0.28 - 0.33

    Generex to Host Satellite Symposium At World Congress on Controversies to Consensus in Diabetes, Obesity & Hypertension
    Wed. October 29, 2008; Posted: 09:01 AM

    www.tradingmarkets.com/.site/news/Sto...

    En voor allen die dit video interview van "Generex Biotechnology on Fox News" nog niet gezien hebben.

    www.foxnews.com/video/index.html?play...

  8. [verwijderd] 30 oktober 2008 14:42

    PRESS RELEASE: Generex Biotechnology Comments On New ADA/EASD Consensus Algorithm for Type 2 Diabetes Treatment
    PRESS RELEASE: Generex Biotechnology Comments On New ADA/EASD Consensus Algorithm for Type 2 Diabetes Treatment

    Generex Biotechnology Comments On New ADA/EASD Consensus

    Algorithm for Type 2 Diabetes Treatment

    Company Believes Generex Oral-lyn(tm) May Play Valuable Role

    in Treatment Paradigm

    WORCESTER, Mass., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Generex

    Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the

    leader in drug delivery for metabolic diseases through the inner lining

    of the mouth, today commented on the consensus algorithm for Type 2

    diabetes treatment issued by the American Diabetes Association (ADA)

    and the European Association for the Study of Diabetes (EASD) published

    online on October 22, 2008 (Diabetes Care, volume 31, number 12,

    December 2008).

    A joint panel of ADA and EASD experts updated the treatment

    recommendations for Type 2 diabetes in a consensus statement which

    provides guidance to health care providers. The algorithm describes a

    stepped-care approach to treat the elevated blood glucose levels that

    characterize diabetes. The first step is comprised of lifestyle

    modifications and metformin. If glucose/glycemic parameters are not met

    or maintained, the algorithm proceeds to the second step which provides

    for either (a) the addition of basal insulin or sulfonylurea, or (b)

    the addition of pioglitazone or a GLP-1 agonist. The algorithm states

    that (a) is the preferred and well-validated approach. If the second

    step paradigm does not meet or maintain glucose/glycemic goals, the

    third step is a transition to intensive insulin therapy.

    In a joint ADA/EASD press release, Dr. David M. Nathan,

    Chair of the Panel, stated: "Excellent glycemic control is critical to

    prevent the long-term complications associated with diabetes, which can

    lead to loss of vision, kidney failure, and amputations."

    Generex believes that Generex Oral-lyn, the Company´s

    proprietary oral insulin spray product which delivers insulin into the

    mouth using the Company´s proprietary RapidMist(tm) drug delivery

    device (with no pulmonary deposition), can play a valuable role in the

    ADA/EASD consensus algorithm.

    As noted by the algorithm, early and aggressive use of

    insulin therapy as the second step of treatment is preferred. Early

    insulin treatment can offer a more rapid restoration of normal blood

    glucose levels and assist in beta cell preservation (beta cells produce

    insulin). Insulin, as a natural hormone produced by the body, is less

    likely to result in side effects.

    However, patients and physicians tend to resist the

    application of insulin therapy because it is delivered by injection.

    The Company believes that Generex Oral-lyn, as a safe, convenient,

    simple, fast, effective, familiar and pain-free alternative to prandial

    insulin injections, can augment the early intervention insulin therapy

    for Type 2 diabetes contemplated by the algorithm and assist in

    delaying the progression of the disease and the onset of its myriad

    complications.

    Generex Oral-lyn is human regular insulin in a liquid

    formulation with small amounts of GRAS excipients delivered into the

    oral cavity with the RapidMist drug delivery system utilizing an

    asthma-like spray. Unlike inhaled insulin products, the micelles that

    are released into the mouth are greater than seven microns and cannot

    enter the lungs. This system allows Generex Oral-lyn to penetrate the

    epithelial lining of the mouth and enter the rich vascular bed beneath.

    This assures rapid appearance in the blood stream, peaking at two

    hours, and because there is no tail of activity as with all other

    insulins, the hypoglycemic risk is minimized. Blood levels return to

    baseline at two hours. This affords great flexibility in usage. The

    simplicity of the system, especially the familiarity of the asthma-like

    device to patients and physician, makes it readily acceptable to

    patients and physicians. Generex Oral-lyn is delivered as a metered

    dose. Essentially, one puff equals one unit of insulin delivered to the

    blood stream. Generex Oral-lyn has proven to be safe and has been

    administered to more than a thousand patients, some for more than a

    year.

    Generex Oral-lyn is presently in the midst of global Phase 3

    clinical trials. To date, 260 subjects have been enrolled in the trials

    at 69 sites in seven countries.

    About Generex Biotechnology Corporation

    Generex is engaged in the research, development and

    commercialization of drug delivery systems and technologies. Generex

    has developed a proprietary platform technology for the delivery of

    drugs into the human body through the oral cavity (with no deposit in

    the lungs). The Company´s proprietary liquid formulations allow drugs

    typically administered by injection to be absorbed into the body by the

    lining of the inner mouth using the Company´s proprietary RapidMist(tm)

    device. The Company´s flagship product, oral insulin (Generex

    Oral-lyn(tm)), which is available for sale in Ecuador and approved for

    sale in India for the treatment of subjects with Type-1 and Type-2

    diabetes, is in Phase III clinical trials at several sites around the

    world. For more information, visit the Generex website at

    www.generex.com.

    The Generex Biotechnology Corp. logo is available at

    www.globenewswire.com/newsroom/prs/?p...

    Safe Harbor Statement

    This release and oral statements made from time to time by

    Generex representatives in respect of the same subject matter may

    contain "forward-looking statements" within the meaning of the Private

    Securities Litigation Reform Act of 1995. These statements can be

    identified by introductory words such as "expects," "plans," "intends,"

    "believes," "will," "estimates," "forecasts," "projects," or words of

    similar meaning, and by the fact that they do not relate strictly to

    historical or current facts. Forward-looking statements frequently are

    used in discussing potential product applications, potential

    collaborations, product development activities, clinical studies,

    regulatory submissions and approvals, and similar operating matters.

    Many factors may cause actual results to differ from forward-looking

    statements, including inaccurate assumptions and a broad variety of

    risks and uncertainties, some of which are known and others of which

    are not. Known risks and uncertainties include those identified from

    time to time in the reports filed by Generex with the Securities and

    Exchange Commission, which should be considered together with any

    forward-looking statement. No forward-looking statement is a guarantee

    of future results or events, and one should avoid placing undue

    reliance on such statements. Generex undertakes no obligation to update

    publicly any forward-looking statements, whether as a result of new

    information, future events or otherwise. Generex cannot be sure when or

    if it will be permitted by
  10. [verwijderd] 31 oktober 2008 13:05
    quote:

    crackedtooth schreef:

    plukje gekocht op 0,30 ivm bodemvorming gister
    puur voor trade
    Ben hier al 3 weken bezig kleine trades te maken.
    Ben met 9000 stukjes begonnen, investering $ 3000,-(echt hobbymatig dus). Inmiddels heb ik zo'n 14000 stukjes waarde $ 4480,-. kleine 50%. Wacht nu even op een forse valse uitbraak ;-)
    M.a.w. koop altijd puur voor de trade.
    Leuke bijkomstigheid is dat de $ ook nog is gestegen;-)
  17. [verwijderd] 7 november 2008 13:38
    The dossier was submitted by Leo Ohanian, managing director of Generex MENA, and Dr. Mustafa Aljabi of Aljabi Drug Store, Damascus. The dossier includes Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product that provides a safe, effective and pain-free alternative to subcutaneous injections of prandial insulin for the treatment of Type I and Type II diabetes. It is estimated that among Syria's population of 20 million, between 3 million and 3.5 million people have diabetes.

    Generex also submitted a file to register its proprietary over-the-counter products, including Glucose RapidSpray(tm), 7-Day Diet Aid Spray(tm) and BaBOOM!(tm) Energy Spray. Glucose RapidSpray(tm) is conveniently packaged to be carried in a purse, pocket, car or other convenient place and is designed for use at the first sign of needing additional glucose. 7-Day Diet Aid Spray(tm) can help dieters satisfy cravings between meals, and BaBOOM!(tm) Energy Spray is an instant and sustaining energy alternative to beverages or shots. All three products are sprayed into the mouth and absorbed into the bloodstream for rapid action.

    The Syrian Ministry of Health will review the dossier and inform Generex of any additional requests for information that they may have. There have been no immediate queries, and Generex anticipates registration before the end of 2009.

    Generex Oral-lyn(tm) was featured last week at the 2nd International Diabetes Federation Regional MENA Diabetes Conference and 17th Annual Meeting of the Syrian Diabetes Association in Lattakia, Syria. The international conference brings together four hundred doctors and endocrinologists from throughout the Middle East and North Africa, whose population suffers from an average diabetes rate of over 20 percent.
  18. gustaaf1e 13 november 2008 18:59
    Toorg,
    je hebt gelijk met je draadje dat vriend Thijs nu weer gesloten heeft. IEX verprutste zelf het forum door iemand toe te staan met zoveel nick-names hier te opereren. Dat kon niet anders dan grote irritatie bij anderen oproepen Het niveau van het forum is daarmee zo ver gedaald dat velen hier nog maar weinig of niet komen. Het was wijzer geweest van IEX om voor daghandelaren een apart forum te openen en dit forum voor beleggers te laten.
    G
703 Posts
Pagina: 1 2 3 4 5 6 ... 36 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 865,36 +0,00%
EUR/USD 1,0650 -0,20%
FTSE 100 7.877,05 +0,37%
Germany40^ 17.743,80 -0,15%
Gold spot 2.384,43 +0,99%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

VIVORY...
+11,51%
JUST E...
+5,71%
Air Fr...
+4,18%
FASTNED
+3,00%
RANDST...
+2,65%

Dalers

Pharming
-9,63%
ASMI
-6,10%
Avantium
-6,01%
PostNL
-5,84%
TomTom
-3,31%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!